Provectus crumbles on FDA 'breakthrough' rejection
This article was originally published in Scrip
Executive Summary
Investors' rebuke of Provectus Pharmaceuticals on 27 May came swift after it confessed it had not received the FDA's breakthrough therapy designation for the firm’s experimental melanoma drug PV-10 (rose bengal disodium in 0.9% saline) – with shares taking an 85% dive.